Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer

Purpose: Randomized evidence for extreme hypofractionation in prostate cancer is lacking. We aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation in a phase 3 randomized trial. Methods and materials: We analyzed...

Full description

Bibliographic Details
Main Authors: Carlos E. Vargas, MD, Matthew Q. Schmidt, MD, Joshua R. Niska, MD, William F. Hartsell, MD, Sameer R. Keole, MD, Lucius Doh, MD, John Han-Chih Chang, MD, Christopher Sinesi, MD, Rossio Rodriquez, CTR, Mark Pankuch, PhD, Gary L. Larson, MD
Format: Article
Language:English
Published: Elsevier 2018-07-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109418300290

Internet

http://www.sciencedirect.com/science/article/pii/S2452109418300290

Similar Items